Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch

Inclusion Criteria: 1. A female or male 18-64 (inclusive) years of age; 2. In good health as determined by medical history and screening exam; 3. Females who are post-menopausal, surgically sterile, or have a negative serum/urine pregnancy test at Day 0 and agree not to become pregnant for the duration of study. Exclusion Criteria: 1. Abnormalities at physical exam \[as determined by the Toxicity Grading Scale (Grade 1-4)\]; 2. Laboratory abnormalities \[as determined by the Toxicity Grading Scale (Grade 1 4)\] at screening; 3. Participated in research involving investigational product within 30 days before planned date of first vaccination; 4. Ever received investigational enterotoxigenic E. coli, LT, or LT (R192G) or NasalFlu, Berna Biotech, Ltd; 5. Women who are pregnant or breastfeeding; 6. Clinically significant underlying enteric, pulmonary, cardiac or renal disease; 7. Current seizure disorder; 8. Current use of immunosuppressive therapy (inhaled steroids are allowed); 9. Known or suspected alcohol abuse or illicit drug use within the last year; 10. Positive Serology for HIV-1, HIV-2, HbsAg, or HCV; 11. Known allergies to any component of the vaccine including adhesives; 12. An employee of the study site; 13. An employee of Intercell (global) or an immediate family member; 14. Visible tattoos or marks (tattoos/scars) at the vaccination areas that would prevent appropriate dermatologic monitoring of the vaccination sites; 15. Receipt of any routine vaccinations within 7 days prior to, or following, the date of planned study vaccinations.